Navigation Links
Venaxis to Present at Three Upcoming Investor Conferences
Date:9/5/2013

CASTLE ROCK, Colo., Sept. 5, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Rodman & Renshaw Annual Global Investment Conference, to be held September 8 – 10, 2013, at the Millennium Broadway Hotel in New York, the Craig-Hallum 4th Annual Alpha Select Conference, to be held September 26, 2013, at the Convene 730 3rd Avenue in New York; as well as the Aegis Capital Vegas Healthcare Conference, to be held September 26 – 28, 2013, at the Wynn Las Vegas Hotel.Event:Rodman & Renshaw Annual Global Investment ConferenceDate: Monday, September 9, 2013 Time: 3:40 pm (Eastern Time) Location:Millennium Broadway Hotel; New York, NY 

Event:Craig-Hallum 4th Annual Alpha Select ConferenceDate: Thursday, September 26, 2013 Time: 3:10 pm (Eastern Time)Location:Flatiron Room; Convene 730 3rd Avenue; New York, NY 

Event:Aegis Capital Vegas Healthcare ConferenceDate: Thursday, September 26, 2013 Time: 11:30 am (Mountain Time) Location:Wynn Las Vegas Hotel; Las Vegas, NVSteve Lundy, President and CEO of Venaxis, will provide an overview of the Company's business at the Rodman & Renshaw and Craig-Hallum Conferences, and Don Hurd, Senior Vice President and Chief Commercial Officer of Venaxis, will present at the Aegis Capital Conference. Mr. Lundy and Mr. Hurd will be available to participate in one-on-one meetings with investors who are registered to attend the respective conferences. 

The Rodman & Renshaw presentation will be webcast. To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com. The webcast replay will remain available for 90 days following each live presentation.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, protein biomarker-based assay for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management. The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. While FDA clearance is being sought, an initial launch for the APPY1 Test is ongoing in select European countries. For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for the APPY1 Test required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1 Test at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the quarter ended June 30, 2013.

For Investors and Media:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, PhD 
jdrumm@tiberend.com; (212) 375-2664

Claire Sojda 
csojda@tiberend.com; (212) 375-2686


'/>"/>
SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Venaxis to Present at Canaccord Genuity 33rd Annual Growth Conference
2. Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors
3. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
4. Venaxis to Present at 25th Annual ROTH Conference
5. Venaxis Presentation Rescheduled for 2013 BIO CEO and Investor Conference
6. Venaxis to Present at 2013 BIO CEO and Investor Conference
7. AspenBio Pharma Changes Company Name to Venaxis, Inc.
8. Soligenix to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
9. Isis Pharmaceuticals to Present at the 2013 Stifel Healthcare Conference
10. Lexicon To Present At The Morgan Stanley Global Healthcare Conference
11. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2013 On September 11, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... DELHI , April 27, 2016 ... CSR initiative to save newborns   ... hospital for women & newborns in collaboration with Breast Milk ... launched the first Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR ... best nutritional food source for infants and should be available ...
(Date:4/27/2016)... April 27, 2016 ... the  "Global Anesthesia Disposables Market 2016-2020"  report ... ) ,The global anesthesia disposables market ... of 4.03% during the period 2016-2020.  ... threat to patients, safety. Organizations like the ...
(Date:4/27/2016)... 2016 The global  gamma ... billion by 2022, according to a new report ... towards a healthy lifestyle is expected to drive ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... health treatment expenditure has urged consumers to switch ...
Breaking Medicine Technology:
(Date:5/1/2016)... San Francisco, California (PRWEB) , ... May 02, ... ... Posters, announces his search for original 1968 Jimi Hendrix Merriweather Post Pavilion in ... Merriweather Post Pavilion Hendrix concert poster. The concert was held on August 16. ...
(Date:5/1/2016)... (PRWEB) , ... May 01, 2016 , ... Outdoor Growing ... medical marijuana industry, has put the law in the hands of the local ... January 1, 2016, California voted to allow counties to vote on growing regulations by ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... Francis Talk Radio with Hypnotherapist, Mary O'Maley. What is hypnosis and hypnotherapy ... control (substances, smoking, weight control), pain relief (chronic and acute), birthing processes and ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... questioned the use of the HyProCure sinus tarsi implant. ( http://www.cbc.ca/news/canada/ottawa/banned-quebec-dentist-pierre-dupont-working-as-chiropodist-in-ottawa-1.3515494 ) ... is a minimally invasive procedure performed, when indicated, to correct the partial ...
(Date:4/29/2016)... , ... April 30, 2016 , ... Mercy College is ... The following programs will be expanding due to high demand: Master of Business ... expansion will begin this summer. , School of Business Graduate Program Chair ...
Breaking Medicine News(10 mins):